Immunic, Inc.
IMUX
$0.8522
$0.00320.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.23% | 2.86% | -2.03% | 15.42% | 16.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.71% | 12.33% | 9.62% | 9.15% | -8.82% |
| Operating Income | -18.71% | -12.33% | -9.62% | -9.15% | 8.82% |
| Income Before Tax | -25.44% | 13.90% | -16.70% | -7.02% | 10.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.44% | 13.90% | -16.70% | -7.02% | 10.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.44% | 13.90% | -16.70% | -7.02% | 10.91% |
| EBIT | -18.71% | -12.33% | -9.62% | -9.15% | 8.82% |
| EBITDA | -18.68% | -12.27% | -9.58% | -9.13% | 8.86% |
| EPS Basic | 3.88% | 17.30% | 48.32% | 52.90% | 60.91% |
| Normalized Basic EPS | 3.87% | 7.91% | 48.33% | 52.90% | 60.93% |
| EPS Diluted | 3.88% | 17.30% | 48.32% | 52.90% | 60.91% |
| Normalized Diluted EPS | 3.87% | 7.91% | 48.33% | 52.90% | 60.93% |
| Average Basic Shares Outstanding | 30.51% | 4.16% | 125.80% | 127.20% | 127.92% |
| Average Diluted Shares Outstanding | 30.51% | 4.16% | 125.80% | 127.20% | 127.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |